ticlopidine has been researched along with Asystole in 13 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Survivors after cardiac arrest (CA) due to AMI undergo PCI and then receive dual antiplatelet therapy." | 6.82 | Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction. ( Bednar, F; Kopa, M; Kroupa, J; Motovska, Z; Ondrakova, M; Osmancik, P, 2016) |
| "The platelet inhibitor clopidogrel is administered to patients treated with therapeutic hypothermia following cardiac arrest due to acute coronary syndromes." | 3.76 | Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. ( Bjelland, TW; Dale, O; Haugen, BO; Hjertner, Ø; Kaisen, K; Klepstad, P, 2010) |
| "Survivors after cardiac arrest (CA) due to AMI undergo PCI and then receive dual antiplatelet therapy." | 2.82 | Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction. ( Bednar, F; Kopa, M; Kroupa, J; Motovska, Z; Ondrakova, M; Osmancik, P, 2016) |
| "After cardiac arrest due to acute coronary syndromes (ACS) therapeutic hypothermia (HT) is the standard care to reduce neurologic damage." | 1.40 | High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. ( Christoph, M; Ibrahim, K; Jellinghaus, S; Kolschmann, S; Mues, C; Pfluecke, C; Quick, S; Schmeinck, S; Schmieder, K; Schoener, L; Steiding, K; Strasser, RH; Wunderlich, C, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reddy C, R | 1 |
| Bompelli, N | 1 |
| Khardenavis, V | 1 |
| Deshpande, A | 1 |
| Ibrahim, K | 1 |
| Christoph, M | 1 |
| Schmeinck, S | 1 |
| Schmieder, K | 1 |
| Steiding, K | 1 |
| Schoener, L | 1 |
| Pfluecke, C | 1 |
| Quick, S | 1 |
| Mues, C | 1 |
| Jellinghaus, S | 1 |
| Wunderlich, C | 1 |
| Strasser, RH | 1 |
| Kolschmann, S | 1 |
| Moudgil, R | 1 |
| Al-Turbak, H | 1 |
| Osborne, C | 1 |
| Hibbert, B | 1 |
| So, DY | 1 |
| Le May, MR | 1 |
| Rosencher, J | 1 |
| Gouffran, G | 1 |
| Bougouin, W | 1 |
| Varenne, O | 1 |
| Bednar, F | 1 |
| Kroupa, J | 1 |
| Ondrakova, M | 1 |
| Osmancik, P | 1 |
| Kopa, M | 1 |
| Motovska, Z | 1 |
| Zaret, BL | 1 |
| Zaret, M | 1 |
| García Paredes, T | 1 |
| Escudero Varela, JC | 1 |
| Mora Ordóñez, JM | 1 |
| Bjelland, TW | 1 |
| Hjertner, Ø | 1 |
| Klepstad, P | 1 |
| Kaisen, K | 1 |
| Dale, O | 1 |
| Haugen, BO | 1 |
| Orban, M | 1 |
| Byrne, RA | 1 |
| Hausleiter, J | 1 |
| Laugwitz, KL | 1 |
| Sibbing, D | 1 |
| Joerg, L | 1 |
| Bridgman, C | 1 |
| Selvanayagam, JB | 1 |
| Avlonitis, VS | 1 |
| Planas, S | 1 |
| Hayes, AM | 1 |
| Parry, A | 1 |
| SoRelle, R | 1 |
| Kawakage, M | 1 |
| Shirakura, S | 1 |
| Karasawa, A | 1 |
| Takeda, M | 1 |
| Miki, I | 1 |
| Ishii, A | 1 |
| Kubo, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CAOCT Study is a Prospective, Multi-centre, Single Cohort, Diagnostic Accuracy Study, Planned to Include 131 Patients in About 3 European Countries After Successful Return of Spontaneous Circulation After Out of Hospital Cardiac Arrest[NCT04431661] | 28 participants (Actual) | Observational | 2021-01-29 | Terminated (stopped due to Low patient recruitment rate and change of hopsital procedures for handling cardiac arrest patients during emergency) | |||
| Definite Stent Thrombosis in Comatose Out of Hospital Cardiac Arrest Survivors Treated With Percutaneous Coronary Intervention and Hypothermia[NCT03312296] | 151 participants (Actual) | Observational | 2016-08-01 | Completed | |||
| Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia[NCT02224274] | Phase 4 | 57 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age[NCT00833703] | Phase 3 | 49 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Platelet activation by adenosine diphosphate (ADP) expressed in arbitrary aggregation units (U). P2Y12 inhibitors block ADP receptors and decrease platelet activation by ADP. Higher values mean less effect of P2Y12 inhibitors, lower values mean more effect of P2Y12 inhibitors on platelets.~High on-treatment platelet reactivity was defined as >46 U." (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | U (Mean) |
|---|---|
| Clopidogrel | 28 |
| Ticagrelor | 15 |
% inhibition reflects P2Y12 inhibitor effect regarding basal platelet reactivity (defined as: (1- (platelet reactivity/basal platelet reactivity)) x 100). Higher values mean better P2Y12 inhibition response. High on-treatment platelet reactivity was defined as <11% inhibition. (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | % inhibition (Mean) |
|---|---|
| Clopidogrel | 4 |
| Ticagrelor | 55 |
Platelet reactivity reflects P2Y12 inhibitor effect. Higher values mean normal platelet reactivity due to low P2Y12 inhibition response, while lower values mean decreased platelet reactivity due to the effect of a P2Y12 inhibitor. High on-treatment platelet reactivity was defined as >208 PRU. (NCT02224274)
Timeframe: 12 h after P2Y12 inhibitor loading
| Intervention | PRU (Mean) |
|---|---|
| Clopidogrel | 238 |
| Ticagrelor | 101 |
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| Spontaneous | Puncture (vascular access site) | |
| Clopidogrel 0.2 mg/kg/Day | 1 | 1 |
| Placebo | 0 | 0 |
"All bleeding events experienced during the study period were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | - Serious | - Serious with an outcome of death | - Leading to permanent treatment discontinuation | |
| Clopidogrel 0.2 mg/kg/Day | 2 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 0 | 0 |
"Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded.~Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first)." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| shunt thrombosis requiring intervention | death | |
| Clopidogrel 0.2 mg/kg/Day | 0 | 0 |
| Placebo | 0 | 1 |
2 trials available for ticlopidine and Asystole
| Article | Year |
|---|---|
Superiority of ticagrelor over clopidogrel in patients after cardiac arrest undergoing therapeutic hypothermia.
Topics: Adenosine; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies | 2014 |
Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction.
Topics: Adenosine; Aged; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; | 2016 |
11 other studies available for ticlopidine and Asystole
| Article | Year |
|---|---|
Scorpion bite-induced ischaemic stroke.
Topics: Animals; Biomarkers; Catecholamines; Cerebral Angiography; Clopidogrel; Fatal Outcome; Female; Heart | 2017 |
High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest.
Topics: Adenosine; Clopidogrel; Female; Flow Cytometry; Heart Arrest; Humans; Hypothermia, Induced; Male; Mi | 2014 |
Optimal antiplatelet therapy in out-hospital cardiac arrest patients treated by primary percutaneous coronary intervention.
Topics: Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Myocardial Infarction; Percutaneous Corona | 2015 |
Purim CPR.
Topics: Attitude of Health Personnel; Cardiology; Cardiopulmonary Resuscitation; Diagnosis, Differential; Em | 2009 |
[Non-occlusive stent thrombosis associated to cardiocirculatory arrest].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosi | 2010 |
Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Midd | 2010 |
Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Midd | 2010 |
Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Midd | 2010 |
Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Midd | 2010 |
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Catecholamines; Clopidogrel; Co | 2011 |
Imaging cardio-vascular anatomy and function in D-Transposition of the great arteries after mustard procedure.
Topics: Adult; Clopidogrel; Heart Arrest; Humans; Magnetic Resonance Angiography; Male; Platelet Aggregation | 2011 |
Occlusion of modified Blalock-Taussig shunt after clopidogrel cessation.
Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Clopidogrel; Fatal Outcome; Graft Occlusion, Vas | 2012 |
The plunger, fine tuned.
Topics: Angina Pectoris; Cardiopulmonary Resuscitation; Clopidogrel; Drug Therapy, Combination; Emergency Tr | 2003 |
Beneficial effect of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate on collagen-induced coronary ischemia in guinea-pigs.
Topics: Animals; Arrhythmias, Cardiac; Benzimidazoles; Benzoxepins; Collagen; Coronary Disease; Cyclooxygena | 1991 |